Vitamin D levels may play role in beating lymphoma

The results of a study carried out at the Mayo Clinic and presented at the meeting of the American Society of Hematology (ASH) suggest that vitamin D levels influence patient survival following standard treatment for diffuse large b-cell lymphoma (DLBCL).

Researchers monitored blood samples taken from 374 patients with previously untreated DLBCL who then underwent treatment involving chemotherapy and discovered that, three years on, patients with a vitamin D deficiency were twice as likely to succomb to their disease as those with sufficient levels in their blood (a vitamin D deficiency was defined in this study as having begun treatment with under 25 nanograms of vitamin D per milliliter of blood).

Researchers were cautious not to make a direct link between vitamin D and lymphoma, and critics of the study noted the lack of controls.

DLBCL is the most common form of non-Hodgkin's lymphoma, accounting for four of every ten new NHL diagnoses. Patients are typically over age 50.

By Ross Bonander

Source: Sciencenews.org

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap